Leukaemia: a model metastatic disease
AE Whiteley, TT Price, G Cantelli, DA Sipkins - Nature Reviews Cancer, 2021 - nature.com
In contrast to solid cancers, which often require genetic modifications and complex cellular
reprogramming for effective metastatic dissemination, leukaemic cells uniquely possess the …
reprogramming for effective metastatic dissemination, leukaemic cells uniquely possess the …
[PDF][PDF] Targeting cancer stemness in the clinic: from hype to hope
Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
Third-line therapy for chronic myeloid leukemia: current status and future directions
J Cortes, F Lang - Journal of Hematology & Oncology, 2021 - Springer
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation
Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …
Cancer stem cells—key players in tumor relapse
M Marzagalli, F Fontana, M Raimondi, P Limonta - Cancers, 2021 - mdpi.com
Simple Summary Cancer is one of the hardest pathologies to fight, being one of the main
causes of death worldwide despite the constant development of novel therapeutic strategies …
causes of death worldwide despite the constant development of novel therapeutic strategies …
[HTML][HTML] Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells
M Carlsten, M Järås - Frontiers in immunology, 2019 - frontiersin.org
Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …